文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

阿巴西普改善β地中海贫血重型患者移植后生存并减少内皮损伤综合征

Abatacept improves posttransplant survival and reduces endothelial injury syndromes in β-thalassemia major.
PubMed 文献 · Blood Adv · 2025-01-01

该回顾性研究比较了64例输血依赖型β地中海贫血患儿在造血干细胞移植中,标准移植物抗宿主病预防方案加或不加阿巴西普的效果。加用阿巴西普组(50例)急性2至4级移植物抗宿主病发生率为0%,无阿巴西普组(14例)为35%;任何内皮损伤综合征发生率分别为16%和64%(P=0.0009)。阿巴西普组无地中海贫血生存率为100%,无阿巴西普组为71%。

要点

  • 加用阿巴西普组急性2至4级GVHD发生率为0%,对照组为35%。
  • 加用阿巴西普组内皮损伤综合征发生率为16%,对照组为64%(P=0.0009)。
  • 阿巴西普组无地中海贫血生存率为100%,对照组为71%。

核心结论

  • 在钙调神经磷酸酶抑制剂为基础的GVHD预防方案中加入阿巴西普,可获得极佳的无地中海贫血生存并降低内皮损伤综合征。

研究设计与样本

  • 回顾性review了在本中心接受HSCT的输血依赖型β地中海贫血患儿,共64例,其中50例接受阿巴西普,14例未接受阿巴西普作为对照。

主要发现

  • 阿巴西普组急性2至4级GVHD发生率为0%,无阿巴西普组为35%。
  • 任何内皮损伤综合征(移植相关TMA、肝窦阻塞综合征、后可逆性脑病和弥漫性肺泡出血)发生率在阿巴西普组为16%,无阿巴西普组为64%(P=0.0009)。
  • 第+14天双链DNA(NETs的替代标志物)和可溶性C5b-9在阿巴西普组低于无阿巴西普组(P=0.04和P<0.001)。
  • 阿巴西普组所有患者均达到完全供者髓系嵌合,并在HSCT后中位末次随访1915天(范围266-3464天)时保持不依赖输血。
  • 无地中海贫血生存率在阿巴西普组为100%,无阿巴西普组为71%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Iron overload in transfusion-dependent β-thalassemia (TDT) generates reactive oxygen species, predisposing to post-hematopoietic stem cell transplant (HSCT) endothelial activation. Abatacept prevents acute graft-versus-host disease (GVHD) by inhibiting CD80/CD86 on T cells, but CD80 is also expressed on neutrophils. Elevated neutrophil extracellular traps (NETs) at day +14 are associated with thrombotic microangiopathy (TMA) after HSCT, mechanistically linking endothelial activation to complement activation. We wanted to compare post-HSCT survival and incidence of endothelial injury syndromes in children with TDT with and without addition of abatacept to standard GVHD prophylaxis. We performed a retrospective review of children with TDT who underwent HSCT at our center. Patients without abatacept served as controls. A total of 64 children underwent HSCT for TDT. Fifty received abatacept and 14 did not. Acute grade 2 to 4 GVHD was lower in the abatacept cohort (0%) compared with the no-abatacept cohort (35%). Incidence of any endothelial injury syndromes (transplant-associated TMA, sinusoidal obstructive syndrome, posterior reversible encephalopathy, and diffuse alveolar hemorrhage) was lower in the abatacept cohort (16%) compared with no abatacept (64%; P = .0009). Day +14 double-stranded DNA (surrogate of NETs) and soluble c5b-9 were lower in the abatacept cohort than the no-abatacept cohort (P = .04 and P < .001, respectively). All patients in the abatacept cohort had full donor myeloid chimerism and remained transfusion independent at a median last follow-up of 1915 days (range, 266-3464) after HSCT. Thalassemia-free survival was 100% in the abatacept cohort and 71% in the no-abatacept cohort. Addition of abatacept to calcineurin inhibitor-based GVHD prophylaxis resulted in excellent thalassemia-free survival and lower endothelial injury syndromes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Khandelwal P, Ibrahimova A, Lane A, et al. Abatacept improves posttransplant survival and reduces endothelial injury syndromes in β-thalassemia major. Blood Adv. 2025. PMID: 40938738. doi:10.1182/bloodadvances.2025017197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。